If you are middle aged and find you have to hold your phone at arm's length to read, you may have presbyopia - a difficulty focusing on close objects that is usually corrected using glasses
Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by the US regulator last year – and has set a new action date o
Think of the R&D dollars that could be saved if artificial intelligence (AI) modelling could tell you at an early stage whether a drug was likely to succeed in clinical trials, and ulti
Boehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance therapy in heart failure with preserved ejection fraction (HFpEF), a form of chr
Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes
Novartis and Hewlett Packard Enterprise (HPE) have agreed to collaborate on the development of digital health technologies, starting with a project to develop a disease surveillance system